Zentiva Snaps Up Alvogen’s CEE Operations
Alvogen To Focus On Asia And Alvotech’s Biosimilars
Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the generics and OTC markets.
You may also be interested in...
Zentiva has announced that Steffen Saltofte will become CEO of the privately-owned generics firm, replacing Nick Haggar who has led the company for over four years.
Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.